REGN Regeneron — — VRTX Vertex Pharma — — MRNA Moderna — — BMRN BioMarin — — CRSP CRISPR Therapeutics — — NTLA Intellia — — BEAM Beam Therapeutics — — RARE Ultragenyx — — ALNY Alnylam — — IONS Ionis Pharma — — SRPT Sarepta — — RCKT Rocket Pharma — — ACAD ACADIA Pharma — — PTGX Protagonist Therap. — — KYMR Kymera Therap. — — IOVA Iovance Biotherapeutics — — MNPR Monopar Therapeutics — — REPL Replimune — — REGN Regeneron — — VRTX Vertex Pharma — — MRNA Moderna — — BMRN BioMarin — — CRSP CRISPR Therapeutics — — NTLA Intellia — — BEAM Beam Therapeutics — — RARE Ultragenyx — — ALNY Alnylam — — IONS Ionis Pharma — — SRPT Sarepta — — RCKT Rocket Pharma — — ACAD ACADIA Pharma — — PTGX Protagonist Therap. — — KYMR Kymera Therap. — — IOVA Iovance Biotherapeutics — — MNPR Monopar Therapeutics — — REPL Replimune — —
Capabilities

Diligence built around
the decision in front of you.

Biotechnology investing demands reading clinical, technical, and financial signals simultaneously. Our work is organized around the three questions that actually determine whether a position works.

01

Clinical Probability of Success

Independent read on whether a trial is designed to succeed — or to impress.

Endpoint & Trial DesignRegulatory PathwayCompetitor Read-ThroughCatalyst TimelineEnrollment FeasibilityHistorical Benchmarking
02

Technical Feasibility

Whether the science and manufacturing can actually deliver what the deck promises.

Platform PlausibilityCMC & ScalabilitySafety Signal ReadDurability of EffectProcess RiskFreedom-to-Operate
03

Financial & Commercial Outlook

A scientific win is not automatically a financial one. We size the real math.

Population SizingPricing & ReimbursementCapital RunwayCompetitive CrowdingCatalyst RealismM&A Optionality
How We Engage

Formats that match how you actually invest.

Single-Name Deep Dive

A full clinical, technical, and financial read on one asset or company ahead of a position, catalyst, or LP decision.

Pre-Deal / Crossover Screen

A faster, focused read timed to a financing round, IPO window, or PIPE — built for a decision that can't wait.

Portfolio Monitoring

Ongoing coverage of names already in a book, with flags raised as new data or regulatory action changes the picture.

Expert Call / Second Opinion

A direct conversation to pressure-test a thesis, a sell-side note, or management's framing before a decision is finalized.

Get Started

Ready for an independent read?

Tell us about the asset and the decision ahead. We'll follow up within one business day.

Request a Briefing